Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-03-16
2010-10-26
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07820690
ABSTRACT:
A method of treating or inhibiting non-digestive tract derived abdominal disorders associated with pain, in particular interstitial cystitis, chronic pelvic pain syndrome and/or abdominal pain associated with endometriosis, in a patient in need thereof, by administering to the patient a pharmaceutically effective amount of a 5-HT3receptor antagonist, in particular cilansetron, or a pharmacologically compatible derivative thereof, such as a salt and/or a solvates.
REFERENCES:
patent: 4845092 (1989-07-01), Sanger et al.
patent: 4939136 (1990-07-01), Haeck et al.
patent: 4942160 (1990-07-01), Sanger et al.
patent: 5063231 (1991-11-01), Sanger et al.
patent: 5977127 (1999-11-01), Bonnacker et al.
patent: 6846823 (2005-01-01), Landau et al.
patent: 7048906 (2006-05-01), Lin et al.
patent: 2004/0019101 (2004-01-01), Karlstadt et al.
patent: 2004/0138252 (2004-07-01), Ikeda et al.
patent: 2005/0070969 (2005-03-01), Gerber
patent: 0 279 512 (1988-08-01), None
patent: 0 297 651 (1989-01-01), None
patent: 0 467 365 (1992-01-01), None
patent: WO 01/41748 (2001-06-01), None
patent: WO 01/87305 (2001-11-01), None
patent: WO 2004/089288 (2004-10-01), None
“An Interview with GI Expert Emeran Mayer, MD” Interstital Cystitis association, Dec. 2000, http://www.ichelp.org/RelatedDiseases/ICAndGIDisturbances.html.
Olden, KW., Clevelan Clinic Journal of Medicine, (Jun. 2003), 70, Suppl. 2, S3-S7.
van de Merwe et al., International Journal of Urology, Oct. 2003, 10 Suppl. S35-38.
Vippagunta et al., Advanced Drug Delivery Reviews, 48 (2001), pp. 3-26.
A.C. Keung et al., Biopharmaceutics & Drug Disposition, 18(4), May 1997, 361-9.
G. Newsome, Journal of the Americal Academy of Nurse Practitioners, 15(2) (2003) 64-71.
Gillenwater et al., J. Urol., 140 (1988) 203-208.
J.C. Bryson, Seminars in Oncology, 19(6) suppl. 15, Dec. 1992, 26-32.
J.N. Krieger et al.,JAMA 282 (1999) 236-237.
Johansen et al., Current Opinion in Urology, Dec. 1, 2002 63-67.
K. Bouchelouche, J. Nordling, Curr.Opin.Urol., 2003; 13:309-13.
M. McNaughton-Collins et al., Ann. Intern. Med., 133 (2000) 367-381.
Maggi et al., J.Auton.Nerv.Sys.,38 (1992)201.
P. Toren et al., International Clinical Pharmacology, 14(6), Nov. 1999, 373-6.
Peeker and Fall, J. Urol., 167 (2002) 2470-2472.
R.M. Moldwin, Current Urology Reports ¾ (2002) 313-318.
Z.H. Israili, Curr. Med. Chem.—CNS Agents 1 (2001) 171-199.
Ronald Wood et al., Automated Noninvasive Measurement of Cyclophosphamide-Induced Changes in Murine Voiding Frequency and Volume,The Journal of Urology, Feb. 2001, pp. 653-659, vol. 165, USA.
Pelvipharm webpage. Accessed Jun. 5, 2009. http://www.pelvipharm.com/index.php?id=49.
Crowell & Moring LLP
Solvay Pharmaceuticals GmbH
Spivack Phyllis G.
LandOfFree
Method of treating or inhibiting a non-digestive tract... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating or inhibiting a non-digestive tract..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating or inhibiting a non-digestive tract... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4201758